ArticleAdvanced healthcare materials2020
Scaffold-Mediated Static Transduction of T Cells for CAR-T Cell Therapy.
Article in Advanced healthcare materials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- A custom two-in-one HIST and line-scanning confocal excitation module.bioRxiv : the preprint server for biology · 2026Article
- Hydrodynamic dispersion drives viral-cellular contact for gene delivery in porous media.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Rapidly dissolving biomaterials for high-efficiency viral transduction.Acta biomaterialia · 2026Article
- Soaking Up Success: Sponge-Assisted Nanoparticle Transfection.Research square · 2026Article
- Lung-targeted RNA delivery systems: strategies and therapeutic applications.Journal of nanobiotechnology · 2026Review
- Advances in integrating biomaterials with CAR-T cells for enhancing solid tumor therapy.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- From saccharides to synthetics: exploring biomaterial scaffolds as cell transduction enhancers.Biomaterials science · 2025Article
- Immunotherapies for locally aggressive cancers.Advanced drug delivery reviews · 2024Review
- Implantable CAR T cell factories enhance solid tumor treatment.Biomaterials · 2024Article
- A biomaterial platform for T cell-specific gene delivery.Acta biomaterialia · 2024Article
- Mechanical forces amplify TCR mechanotransduction in T cell activation and function.Applied physics reviews · 2024Review
- Review
- Recent Advancements in Biomaterials for Chimeric Antigen Receptor T Cell Immunotherapy.Biomaterials research · 2024Review
- Biomaterials-Mediated Engineering of the Immune System.Annual review of immunology · 2023Review
- Absorption rate governs cell transduction in dry macroporous scaffolds.Biomaterials science · 2023Article
- Recent advances in microfluidic-based cancer immunotherapy-on-a-chip strategies.Biomicrofluidics · 2023Review
- Three-dimensional (3D) scaffolds as powerful weapons for tumor immunotherapy.Bioactive materials · 2022Review
- Restoring Carboxylates on Highly Modified Alginates Improves Gelation, Tissue Retention and Systemic Capture.Acta biomaterialia · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Chimeric antigen receptor T (CAR-T) cell therapy has produced impressive clinical responses in patients with B-cell malignancies. Critical to the success of CAR-T cell therapies is the achievement of robust gene transfer into T cells mediated by viral vectors such as gamma-retroviral vectors. However, current methodologies of retroviral gene transfer rely on spinoculation and the use of retronectin, which may limit the implementation of cost-effective CAR-T cell therapies. Herein, a low-cost, tunable, macroporous, alginate scaffold that transduces T cells with retroviral vectors under static condition is described. CAR-T cells produced by macroporous scaffold-mediated viral transduction exhibit >60% CAR expression, retain effector phenotype, expand to clinically relevant cell numbers, and eradicate CD19
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.